In April 2006, Neuronyx, founded in 1999 by the late biotechnology scientist and entrepreneur Hubert J.P. Schoemaker, received a green light from the institutional review board at the Arizona Heart Institute, where the study involving up to 18 patients will be conducted. The company will begin testing its experimental adult stem-cell therapy treatment in human patients for the first time in May 2006.

President and CEO Steven Webster said the therapy involves injecting heart attack patients with stem cells harvested from adult bone marrow 30 days after their attack to preserve and potentially repair damaged heart tissue. The dosage will range from 30 million to 300 million stem cells. In preclinical testing on animals the treatment showed the ability to regenerate damaged tissue.

0 Comments:

About Me

I'm a patent lawyer located in central New Jersey. I have a J.D. from the University of Chicago and a Ph.D. from Stanford University, where I studied graphite intercalation compounds at the Center for Materials Research. I worked at Exxon Corporate Research in areas ranging from engine deposits through coal and petroleum to fullerenes. An article that I wrote in The Trademark Reporter, 1994, 84, 379-407 on color trademarks was cited by Supreme Court in Qualitex v. Jacobson, 514 US 159 (1995) and the methodology was adopted
in the Capri case in N.D. Ill. An article that I wrote on DNA profiling was cited by the Colorado Supreme Court (Shreck case) and a Florida appellate court (Brim case). I was interviewed by NHK-TV about the Jan-Hendrik Schon affair. I am developing ipABC, an entity that combines rigorous IP analytics with study of business models, to optimize utilization of intellectual property. I can be reached at C8AsF5 at yahoo.com.